Refrakcione greške kod prevremeno rođene dece sa prematurnom retinopatijom nakon terapije antivaskularnim endotelnim faktorom rasta (anti-VEGF)

  • Milena S. Vujanović Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
  • Gordana Lj. Stanković-Babić Faculty of Medicine, University of Niš, Niš, Serbia
  • Ana Oros Clinic for Eye Diseases, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Gordana D. Zlatanović Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
  • Predrag Jovanović Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
  • Sonja P. Cekić Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
  • Branislav Tomašević Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
  • Jasmina M. Djorđević-Jocić Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
DOI: https://doi.org/10.2298/VSP150831191V
Ključne reči: retinopathy of prematurity||, ||retinopatija kod prematurusa, refraction, ocular||, ||oko, refrakcija, diagnostic techniques and procedures||, ||dijagnostičke tehnike i procedure, myopia||, ||miopija, astigmatism||, ||astigmatizam, vascular endothelial growth factors||, ||faktori rasta endotela krvnih sudova,

Sažetak


Uvod/Cilj. Prematurna retinopatija (retinopathy of prematurity, ROP) je vazoproliferativna retinopatija koja deluje na krvne sudove retine tokom njenog razvoja. Cilj rada bio je proceniti učestalost i stepen refrakcionih anomalija kod prevremeno rođene dece sa teškom formom ROP, a koja su lečena anti-vaskularnim endotelnim faktorom rasta (anti-VEGF) (bevacizumab). Metode. Prospektivnom studijom obuhvaćeno je 21 dete (42 oka), starosti devet meseci, kod kojih je zbog teške forme ROP primenjena anti-VEGF terapija. Kontrolnu grupu činilo je 45 dece (90 očiju) kod kojih je primenjena laser fotokoagulacija. Kod svakog deteta nakon cikloplegije urađena je retinoskopija, keratorefraktometrija i A-scan ultrasonografija. Rezultati. Miopija je bila prisutna kod 47,62% očiju studijske grupe i kod 33,33% očiju kontrolne grupe, ali bez statistički značajne razlike između njih. Visoka miopija (stem ekvivalent – SE < -3.0 dioptrije – D) bila je zastupljena kod 16,67% očiju studijske grupe i kod 18,19% očiju kontrolne grupe. Klinički značajna hipermetropija bila je češća u studijskoj nego u kontrolnoj grupi (47,62% vs 34,44%). Visoka hipermetropija bila je mnogo zastupljenija u kontrolnoj grupi (15,56% vs 11,90%; p < 0,001). Astigmatizam, posebno visoki, bio je mnogo učestaliji u kontrolnoj grupi nego u studijskoj grupi. Najčešća forma astigmatizma u obe grupe bio je pravilan astigmatizam. Anisometropija bila je mnogo češća u kontrolnoj grupi (24,44%) nego u studijskoj grupi (9.52%) (p < 0.05). U studijskoj grupi bila je značajno veća debljina sočiva i plića prednja očna komora nego u kontrolnoj grupi. U dužini oka nije bilo značajne razlike između očiju ispitivanih grupa. Zaključak. Kod bolesnika sa ROP, kod kojih je primenjena anti-VEGF terapija, kratkovidost je bila prisutna, ali visoka kratkovidost manje nego u grupi ispitanika lečenih laserom. Ova činjenica je verovatno u vezi sa razvojem prednjeg segmenta oka, te je za praćenje uticaja anti-VEGF terapije na razvoj refrakcionog statusa oka potreban duži vremenski period i veći broj ispitanika.

Biografije autora

Milena S. Vujanović, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
ophthalmologist, MD
Gordana Lj. Stanković-Babić, Faculty of Medicine, University of Niš, Niš, Serbia

ophthalmologist, PhD

 

Ana Oros, Clinic for Eye Diseases, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

ophthalmologist, PhD

Gordana D. Zlatanović, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia

ophthalmologist, PhD

Predrag Jovanović, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia

ophthalmologist, PhD

Sonja P. Cekić, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
ophthalmologist, PhD
Branislav Tomašević, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia
ophthalmologist, MD
Jasmina M. Djorđević-Jocić, Clinic for Eye Diseases, Clinical Center Niš, Niš, Serbia; Faculty of Medicine, University of Niš, Niš, Serbia
ophthalmologist, PhD

Reference

Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of pre-maturity and risk factors: A prospective cohort study. BMC Pediatr 2005; 5(1): 18.

Higgins R. 50 years ago in the journal of pediatrics: Incidence of retrolental fibroplasis: past and present. J Pediatr 2009; 148: 6.

Keshet E. Preventing pathological regression of blood vessels. J Clin Invest 2003; 112(1): 27−9.

Olujic M, Oros A, Bregun-Doronjski A, Velisavljev-Filipovic G. Fac-tors given by birth and oxygenotherapy in relation to devel-opment of retinopathy of prematurity. Med Pregl 2012; 65(7−8): 326−30.

Chen T, Tsai T, Shih Y, Yeh P, Yang C, Hu F, et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010; 51(12): 6140−8.

Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P. Characteristics of Infants With Severe Retinopathy of Prema-turity in Countries With Low, Moderate, and High Levels of Development: Implications for Screening Programs. Pediatrics 2005; 115(5): e518−25.

Good WV. The Early Treatment for Retinopathy Of Prematur-ity Study: Structural findings at age 2 years. Br J Ophthalmol 2006; 90(11): 1378−82.

Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: Ana-tomical and refractive outcomes. Retina (Philadelphia, Pa) 2008; 28(6): 839−46.

Quinn GE, Dobson V, Kivlin J, Kaufman LM, Repka MX, Reynolds JD, et al. Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of pre-maturity. Cryotherapy for Retinopathy of Prematurity Cooper-ative Group. Ophthalmology 1998; 105(7): 1292−300.

Quinn GE, Dobson V, Siathowski R, Hardy R, Kilvin J, Palmer E, et al. Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 2001; 108(2): 343−7.

Connolly BP, Ng EY, McNamara AJ, Regillo CD, Vander JF, Tas-man W. A comparison of laser photocoagulation with cryothe-rapy for threshold retinopathy of prematurity at 10 years: Part 2. Refractive outcome. Ophthalmology 2002; 109(5): 936−41.

Dhawan A, Dogra M, Vinekar A, Gupta A, Dutta S. Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity. J Pediatr Oph-thalmol Strabismus 2008; 45(6): 356−61.

McLoone EM, Keefe MO, McLoone SF, Lanigan BM. Long-term refractive and biometric outcomes following diode laser thera-py for retinopathy of prematurity. J AAPOS 2006; 10(5): 454−9.

Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Coop-erative Group . Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity. N Engl J Med. 2011; 364(7): 603−15.

Trese MT. Update on Anti-VEGF Treatment for ROP. Retina Today 2013; 2(8): 57−9.

Harder BC, Baltz S, Schlichtenbrede FC, Jonas JB. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol 2012; 130(6): 800−1.

Harder BC, Schlichtenbrede FC, Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematur-ity: Refractive error results. Am J Ophthalmol 2013; 155(6): 1119−24.

Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening ex-amination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117(2): 572−6.

International Committee for the Classification of Retinopathy of Prema-turity. The International Classification of Retinopathy of Pre-maturity revisited. Arch Ophthalmol 2005; 123(7): 991−9.

Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233−48; discussion 248−50.

Chen YH, Chen SN, Lien RI, Shih CP, Chao AN, Chen KJ, et al. Refractive errors after the use of bevacizumab for the treat-ment of retinopathy of prematurity: 2-year outcomes. Eye (Lond) 2014; 28(9): 1080−6; quiz 1087.

Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizu-mab monotherapy compared with conventional laser treat-ment: A randomized clinical trial. JAMA Ophthalmol 2014; 132(11): 1327−33.

Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analy-sis. Ophthalmology 2015; 122(5): 1008−15.

Martínez-Castellanos MA, Schwartz S, Hernández-Rojas ML, Kon-Jara VA, García-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of pre-maturity up to 5 years of follow-up. Retina (Philadelphia, Pa.) 2013; 33(2): 329−38.

Repka MX. Refraction and keratometry in premature infants. Br J Ophthalmol 2004; 88(7): 853−4.

Wang J, Ren X, Shen L, Yanni SE, Leffler JN, Birch EE. Devel-opment of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci 2013; 54(9): 6018−24.

Fledelius HC, Fledelius C. Eye size in threshold retinopathy of prematurity, based on a Danish preterm infant series: Early axial eye growth, pre- and postnatal aspects. Invest Ophthal-mol Vis Sci 2012; 53(7): 4177−84.

Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol 2013; 91(4): e276−82.

Davitt BV, Dobson V, Quinn GE, Hardy RJ, Tung B, Good WV, et al. Early Treatment for Retinopathy of Prematurity Cooper-ative Group. Astigmatism in the Early Treatment for Retino-pathy of Prematurity Study: Findings to 3 years of age. Oph-thalmology 2009; 116(2): 332−9.

Davitt BV, Quinn GE, Wallace DK, Dobson V, Hardy RJ, Tung B, et al. Astigmatism progression in the early treatment for reti-nopathy of prematurity study to 6 years of age. Ophthalmolo-gy 2011; 118(12): 2326−9.

Yang CS, Wang AG, Shih YF, Hsu WM. Astigmatism and bio-metric optic components of diode laser-treated threshold reti-nopathy of prematurity at 9 years of age. Eye (Lond) 2013; 27(3): 374−81.

Objavljeno
2017/06/28
Broj časopisa
Vol. 74 Br. 4 (2017)
Rubrika
Originalni članak